Online inquiry

IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4980MR)

This product GTTS-WQ4980MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA2B&ITGB3 gene. The antibody can be applied in Platelet aggregation research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000419.5; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3674; 3690
UniProt ID P08514; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4980MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4238MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ2306MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ11422MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ4465MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ8742MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ9662MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ14383MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ13978MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW